U.S., Oct. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07219173) titled 'A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma' on Oct. 20.
Brief Summary: The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma.
Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Asthma
Intervention:
DRUG: Brenipatide
Administered SC
DRUG: Brenipatide
Administered SC
DRUG: Placebo
Administered SC
Recruitment...